The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma

Gene Therapy

Volumn 19, Issue 7, 2012, Pages 734-741

  Kiyohara, E ^a,b   Tamai, K ^a,b   Katayama, I ^b   Kaneda, Y ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

chemotherapy; HVJ E; immunotherapy; melanoma; Rad51

Indexed keywords

ANTINEOPLASTIC AGENT; DACARBAZINE; HEMAGGLUTINATING VIRUS OF JAPAN ENVELOPE; KU ANTIGEN; RAD51 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL DEATH; COLONY FORMATION; DOUBLE STRANDED DNA BREAK; DRUG POTENTIATION; FEMALE; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, NUCLEAR; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RAD51 RECOMBINASE; RNA, SMALL INTERFERING; SENDAI VIRUS; SKIN NEOPLASMS;

MUS; SENDAI VIRUS;

EID: 84863724374     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.123     Document Type: Article

References (35)

1. Atkins MB, Buzaid AC, Houghton AN. Systemic chemotherapy and biochemotherapy. In: Balch CM et al. (eds). Cutaneous Melanoma, 4th edn. Quality Medical Publishing: St Louis, 2003, pp 589-604.
2. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-2751. (Pubitemid 29415231)
3. Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001; 11: 75-81. (Pubitemid 32158188)
4. Tom C, Reg F, Bernadette C, Malcolm M. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2000; 2: CD001215.
5. Peter B, Stephen CW. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci 1998; 23: 247-251.
6. Maacke H, Jost K, Opitz S, Miska S, Yuan Y, Hasselbach L et al. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 2000; 19: 2791-2795. (Pubitemid 30339230)
7. John T. The Rad51 gene family, genetic instability and cancer. Cancer Lett 2005; 219: 125-135.
8. Makoto I, Seiji Y, Keisuke N, Kazuya H, Hiraoka K, Tamai K et al. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 2005; 7: 1044-1052. (Pubitemid 41195066)
9. Jonathan AFH, Juehui L, Zhu QS, Bolshakov SV, Li L, Pisters PW et al. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther 2007; 6: 1651-1659.
10. Elke R, Karen S, Susanne F, Vanessa S, Schweiger S, Haaf T et al. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 2002; 62: 219-225. (Pubitemid 34074008)
11. Kondo Y, Fushikida K, Fujieda T, Sakai K, Miyata K, Kato F et al. Efficient delivery of antibody into living cells using a novel HVJ envelope vector system. J Immunol Meth 2008; 332: 10-17.
12. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002; 6: 219-226. (Pubitemid 36336129)
13. Takami Y, Nakagami H, Morishita R, Katsuya T, Cui TX, Ichikawa T et al. Ubiquitin carboxy-terminal hydrolase L1, a novel deubiquitinating enzyme in the vasculature, attenuates NF-kB activation. Arterioscler Thromb Vasc Biol 2007; 27: 2184-2190. (Pubitemid 350287248)
14. Kurooka M, Kaneda Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res 2007; 67: 227-236. (Pubitemid 46142779)
15. Fujuhara A, Kurooka M, Miki T, Kaneda Y. Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol Immunother 2008; 57: 73-84. (Pubitemid 350043650)
16. Matsuda M, Yamamoto T, Matsumura A, Kaneda Y. Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope. Gene Therapy 2009; 16: 1465-1476.
17. Emmy PR, Duane RP, Ann HO, Ivanova VS, Bonner WM. DNA double-strand breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273: 5858-5868. (Pubitemid 28124064)
18. Thomas S, Sarah AW, Karen C, Goodarzi AA, Petermann E, Concannon P et al. ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling. EMBO 2006; 25: 5775-5782. (Pubitemid 44967761)
19. Ashby JM, Xuetong S. DNA repair in the context of chromatin. Cell Cycle 2005; 4: 568-571.
20. Christoph H, Barbara P, Christiane T, Winter D, Fink D, Kovacic B et al. Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol 2005; 124: 1300-1307. (Pubitemid 40847419)
21. Emma B, Derek JR, Bin-Bing SZ, Kum KK. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res 2009; 15: 6314-6320.
22. Nicola JC. PARP inhibitors for cancer therapy. Expert Rev Mol Med 2005; 15: 603-617.
23. Christopher MH, Andrei S, Vera G. Use of the Rad51 promoter for targeted anti-cancer therapy. Proc Natl Acad Sci USA 2008; 105: 20810-20815.
24. Jen-Chung K, Shih-Ci C, Chau-Ming C, Wang LH, Hong JH, Jheng MYet al. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. Carcinogenesis 2008; 29: 1448-1458.
25. Artur S, Christoph S, Gregory T, Nieborowska-Skorska M, Hoser G, Nowicki MO et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001; 8: 795-806. (Pubitemid 33030213)
26. Jeffery SR, Kristin B, William EB, Cerra MA, Oswaid KA, Camphausen K et al. Gleevecmediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 2003; 63: 7377-7383. (Pubitemid 37413479)
27. Roman T, kerstin F, John T, Kaina B. Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide. Cancer Lett 2006; 239: 305-313. (Pubitemid 43977859)
28. Bolderson E, Richard DJ, Zhou BBS, Khanna KK. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res 2009; 15: 6314-6320.
29. Eric W, David JC. The endless tale of non-homologous end-joining. Cell Res 2008; 18: 114-124.
30. Olszewska-Slonina DM, Styczynisk J, Drewa TA, Olszewski KJ, Czajkowski R. B16 and cloudman S91 mouse melanoma cells susceptibility to apoptosis after dacarbazine treatment. Acta Pol Pharm 2005; 62: 473-483.
31. Min H, Ze-Hong M, Hong Z, Yu-Jun C, Wei L, Jian D. Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Mol Cancer Ther 2008; 7: 1440-1449.
32. Kim J, Kim PH, Yoo JY, Yoon AR, Choi HJ, Seong J et al. Double E1B 19kDa-and E1B 55 kDa-deleted oncolytic adenovirus in combination with radiotherapy elicits an enhanced anti-tumor effect. Gene Therapy 2009; 16: 1111-1121.
33. Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008; 26: 5748-5754.
34. Masayuki S, Masumi H, Yasumitsu T, Takano TY, Nakatsu Y, Tsuzuki T et al. Modes of actions of two types of anti-neoplastic drugs, dacarbazine and ACNU, to induce apoptosis. Carcinogenesis 2007; 28: 2657-2663. (Pubitemid 350238970)
35. Saga K, Tamai K, Kawachi M, Shimbo T, Fujita H, Yamazaki T et al. Functional modification of Sendai virus by siRNA. J Biotechnol 2008; 133: 386-394. (Pubitemid 50018953)